Shattuck Labs presents preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
– SL-9258 (TIGIT-Fc-LIGHT) Associated with Expanded Anti-PD(L)1 Anti-Tumor Activity of Checkpoint Antibodies in Aggressive CPI-Resistant Tumors –
-BShattuck utyrophilin heterodimeric fusion proteins The GADLEN platform showed better destruction of tumor cells targeting CD19 and CD20 and preclinical proof of concept demonstrated in cancer treatment –
AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic drugs for the treatment of patients with cancer and autoimmune diseases, preclinical data announced today at the 2022 Annual Meeting of the American Association for Cancer Research (AACR). This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform and the company’s GADLEN platform.
“We have made excellent progress advancing compounds in our preclinical pipeline,” said Taylor Schreiber, MD, Ph.D., president and CEO of Shattuck. “Data from our compound SL-9258 indicate potent modulation of myeloid cells, T cells, and cytokines, including IL-2, which collectively resulted in superior antitumor activity compared to TIGIT and PD- L1 in a preclinical model of acquired MP-1 resistance Additionally, several compounds from our gamma delta T-cell engagement platform, or GADLEN, have shown specific anti-tumor activity in preclinical studies, which will help guide our selection of lead candidates and our clinical development strategy. We look forward to nominating our next clinical product candidate in 2022.”
The details of the presentations are as follows:
Title of abstract: LIGHT (TNFSF14) Costimulation with TIGIT Blockade Expands Checkpoint Inhibitor (CPI) Activity in Refractory and Checkpoint Inhibitor-Resistant Tumors Through Targeted Activation of Myeloid Cells and Effector Lymphocytes
Shattuck presented preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrating that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands and expands immune costimulation by the TNF ligand known as LIGHT. LIGHT’s ability to bind and activate CD8+ T cells and natural killer cells through interactions with one of its receptors known as HVEM and myeloid cells through interactions with its another receptor known as LTbR, results in strong anti-tumor responses in primary and acquired resistance murine tumors. models, where antibodies blocking TIGIT show no activity.
TIGIT-Fc-LIGHT was evaluated and well tolerated in non-human primates at doses up to 40 mg/kg and similar targeted pharmacodynamic activity was observed compared to what was preclinically characterized in mice. Together, these results suggest that TIGIT-Fc-LIGHT may provide clinical benefit to patients refractory to conventional checkpoint blockade therapy.
Abstract Title: Bispecific gamma/delta T cell engagers containing the heterodimeric butyrophilin 2A1/3A1 fusion protein effectively activate Vg9Vd2+ T cells and promote tumor cell killing
Shattuck presented preclinical data highlighting the potential of GADLENs to direct gamma delta T cells to kill tumor cells and, in doing so, further elucidate tumor cell markers that are important for the therapeutic activity of GADL-based therapies. gamma delta T cells.
Bispecific Shattuck GADLENs containing BTN2A1 and BTN3A1 heterodimeric extracellular domains fused via inert Fc linkers to scFv domains, targeting CD19 or CD20 tumor antigens, have demonstrated an ability to induce proliferation, degranulation and cytokine production in Vg9Vd2+ T cells with co-stimulation of a natural cytotoxicity receptor or T-cell co-stimulation receptor. In addition, CD19- and CD20-directed GADLENs enhanced the specific killing of lymphoma cells that express both antigenic targets.
Additional information about the meeting is available on the AACR website, https://www.aacr.org. Posters will be available under Posters on the Society’s website shortly after the event.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic drugs for the treatment of patients with cancer and autoimmune diseases. Compounds derived from Shattuck’s proprietary agonist redirected checkpoint, ARC®, the platform simultaneously inhibits checkpoint molecules and activates costimulatory molecules within the same therapy. The Company’s SL-172154 (SIRPα-Fc-CD40L) program, designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a phase 1 trial in solid tumors or lymphomas. In addition, the company is developing a proprietary GADLEN™ platform, Gamma Delta T Cell Engager, which is designed to link gamma delta T cells to tumor antigens for the treatment of cancer patients. Shattuck has offices in Austin, TX and Durham, NC. For more information, please visit: www.ShattuckLabs.com.
Investor contacts:
Conor Richardson
Senior Director, Finance and Investor Relations
Shattuck Labs, Inc.
[email protected]
Media Contact:
Stephanie Asher
General director
Stern Investor Relations, Inc.
[email protected]
